Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProMIS NeurosciencesPMN -7.30%35 EV-to-EBIT is -1.44 as of Aug. 02, 2026. GuruFocus rates PMN with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 387 Biotechnology companies, ProMIS Neurosciences ranks worse than 258397.67% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ProMIS Neurosciences's Enterprise Value for the quarter that ended in Mar. 2026 was $50.05 Mil.
ProMIS Neurosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences EV-to-EBIT Related Terms
ProMIS Neurosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ProMIS Neurosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's EV-to-EBIT falls into.
ProMIS Neurosciences's current Enterprise Value is $59.10 Mil.
ProMIS Neurosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences (PMN) has a EV-to-EBIT of -1.44 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #999999 out of 387 companies in the Biotechnology industry.
Is ProMIS Neurosciences' EV-to-EBIT too high?
ProMIS Neurosciences' current EV-to-EBIT is -1.44. Based on the distribution chart, ProMIS Neurosciences ranks #999999 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProMIS Neurosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' EV-to-EBIT compare to FBIO and VANI?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #999999 out of 387 companies for EV-to-EBIT. This places ProMIS Neurosciences in the lower half of its industry. The industry median EV-to-EBIT is 12.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ProMIS Neurosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current EV-to-EBIT is -1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current EV-to-EBIT of -1.44. The current EV-to-EBIT is -1.44. ProMIS Neurosciences' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current EV-to-EBIT is -1.44 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
35GF Score
Get the complete analysis for PMN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
